Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 106

1.

A systematic review on topoisomerase 1 inhibition in the treatment of metastatic breast cancer.

Kümler I, Brünner N, Stenvang J, Balslev E, Nielsen DL.

Breast Cancer Res Treat. 2013 Apr;138(2):347-58. doi: 10.1007/s10549-013-2476-3. Epub 2013 Mar 20. Review.

PMID:
23512247
[PubMed - indexed for MEDLINE]
2.

Combined topoisomerase I inhibition for the treatment of metastatic colon cancer.

Holcombe RF, Kong KM, Wimmer D.

Anticancer Drugs. 2004 Jul;15(6):569-74.

PMID:
15205598
[PubMed - indexed for MEDLINE]
3.

Phase I clinical trial of weekly combined topotecan and irinotecan.

Lokich J.

Am J Clin Oncol. 2001 Aug;24(4):336-40.

PMID:
11474256
[PubMed - indexed for MEDLINE]
4.

Phase II study of oral vinorelbine in combination with capecitabine as second line chemotherapy in metastatic breast cancer patients previously treated with anthracyclines and taxanes.

Jones A, O'Brien M, Sommer H, Nowara E, Welt A, Pienkowski T, Rolski J, Pham ML, Perraud K, Trillet-Lenoir V.

Cancer Chemother Pharmacol. 2010 Mar;65(4):755-63. doi: 10.1007/s00280-009-1081-y. Epub 2009 Aug 9.

PMID:
19669644
[PubMed - indexed for MEDLINE]
5.

Two schedules of etirinotecan pegol (NKTR-102) in patients with previously treated metastatic breast cancer: a randomised phase 2 study.

Awada A, Garcia AA, Chan S, Jerusalem GH, Coleman RE, Huizing MT, Mehdi A, O'Reilly SM, Hamm JT, Barrett-Lee PJ, Cocquyt V, Sideras K, Young DE, Zhao C, Chia YL, Hoch U, Hannah AL, Perez EA; NKTR-102 Study Group.

Lancet Oncol. 2013 Nov;14(12):1216-25. doi: 10.1016/S1470-2045(13)70429-7. Epub 2013 Oct 4.

PMID:
24095299
[PubMed - indexed for MEDLINE]
6.

Randomized phase II study of two irinotecan schedules for patients with metastatic breast cancer refractory to an anthracycline, a taxane, or both.

Perez EA, Hillman DW, Mailliard JA, Ingle JN, Ryan JM, Fitch TR, Rowland KM, Kardinal CG, Krook JE, Kugler JW, Dakhil SR.

J Clin Oncol. 2004 Jul 15;22(14):2849-55.

PMID:
15254052
[PubMed - indexed for MEDLINE]
Free Article
7.

New advances in lung cancer chemotherapy: topotecan and the role of topoisomerase I inhibitors.

Huang CH, Treat J.

Oncology. 2001;61 Suppl 1:14-24. Review.

PMID:
11598410
[PubMed - indexed for MEDLINE]
8.

[Topoisomerase I inhibitors. Review of phase II trials with irinotecan (CPT-11) and topotecan].

Bonneterre J.

Bull Cancer. 1995 Aug;82(8):623-8. Review. French.

PMID:
7492818
[PubMed - indexed for MEDLINE]
9.

The use of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer: systematic review and economic evaluation.

Hind D, Tappenden P, Tumur I, Eggington S, Sutcliffe P, Ryan A.

Health Technol Assess. 2008 May;12(15):iii-ix, xi-162. Review.

PMID:
18462574
[PubMed - indexed for MEDLINE]
Free Article
10.

Irinotecan plus fluorouracil/leucovorin for metastatic colorectal cancer: a new survival standard.

Saltz LB, Douillard JY, Pirotta N, Alakl M, Gruia G, Awad L, Elfring GL, Locker PK, Miller LL.

Oncologist. 2001;6(1):81-91.

PMID:
11161231
[PubMed - indexed for MEDLINE]
Free Article
11.

N0332 phase 2 trial of weekly irinotecan hydrochloride and docetaxel in refractory metastatic breast cancer: a North Central Cancer Treatment Group (NCCTG) Trial.

Tan WW, Hillman DW, Salim M, Northfelt DW, Anderson DM, Stella PJ, Niedringhaus R, Bernath AM, Gamini SS, Palmieri F, Perez EA.

Ann Oncol. 2010 Mar;21(3):493-7. doi: 10.1093/annonc/mdp328. Epub 2009 Jul 22.

PMID:
19625343
[PubMed - indexed for MEDLINE]
Free Article
12.

Phase 2 study of gemcitabine and irinotecan in metastatic breast cancer with correlatives to determine topoisomerase I localization as a predictor of response.

Moulder S, Valkov N, Neuger A, Choi J, Lee JH, Minton S, Munster P, Gump J, Lacevic M, Lush R, Sullivan D.

Cancer. 2008 Nov 15;113(10):2646-54. doi: 10.1002/cncr.23916.

PMID:
18823053
[PubMed - indexed for MEDLINE]
Free Article
13.

Ixabepilone: clinical role in metastatic breast cancer.

Denduluri N, Swain S.

Clin Breast Cancer. 2011 Jun;11(3):139-45. doi: 10.1016/j.clbc.2011.03.009. Epub 2011 Apr 20. Review.

PMID:
21665133
[PubMed - indexed for MEDLINE]
14.

[Evaluation of irinotecan hydrochloride (CPT-11) and trastuzumab combination therapy as salvage treatment in patients with HER2 overexpressing metastatic breast cancer].

Ikeda M, Kurebayashi J, Sonoo H, Oota Y, Fujii S, Shimo T, Miyake A, Seki M, Souda M, Nomura T, Yamamoto Y, Shiiki S, Nakashima K, Tanaka K.

Gan To Kagaku Ryoho. 2009 May;36(5):773-7. Japanese.

PMID:
19461176
[PubMed - indexed for MEDLINE]
15.

[Clinical activity spectrum of irinotecan].

Cottu PH, Extra JM, Lerebours F, Espie M, Marty M.

Bull Cancer. 1998 Dec;Spec No:21-5. Review. French.

PMID:
9932080
[PubMed - indexed for MEDLINE]
16.

[Topotecan: prospects for using it in combination therapy for ovarian carcinoma].

Scarfone G.

Tumori. 1999 Nov-Dec;85(6 Suppl 1):S12-5. Italian.

PMID:
10786195
[PubMed - indexed for MEDLINE]
17.

Salvage treatment with topotecan in patients with irinotecan-refractory small cell lung cancer.

Park SH, Cho EK, Kim Y, Kyung SY, An CH, Lee SP, Park JW, Jeong SH, Lee JI, Choi SJ, Park J, Shin DB, Lee JH.

Cancer Chemother Pharmacol. 2008 Nov;62(6):1009-14. doi: 10.1007/s00280-008-0690-1. Epub 2008 Feb 8.

PMID:
18259751
[PubMed - indexed for MEDLINE]
18.

Phase I study of topotecan and cisplatin in patients with advanced solid tumors: a cancer and leukemia group B study.

Miller AA, Hargis JB, Lilenbaum RC, Fields SZ, Rosner GL, Schilsky RL.

J Clin Oncol. 1994 Dec;12(12):2743-50.

PMID:
7527456
[PubMed - indexed for MEDLINE]
Free Article
19.

Phase II study of sequentially administered low-dose mitomycin-C (MMC) and irinotecan (CPT-11) in women with metastatic breast cancer (MBC).

Mrozek E, Kolesar J, Young D, Allen J, Villalona-Calero M, Shapiro CL.

Ann Oncol. 2008 Aug;19(8):1417-22. doi: 10.1093/annonc/mdn154. Epub 2008 Apr 11.

PMID:
18407955
[PubMed - indexed for MEDLINE]
Free Article
20.

Review of the contemporary cytotoxic and biologic combinations available for the treatment of metastatic breast cancer.

Tkaczuk KH.

Clin Ther. 2009;31 Pt 2:2273-89. doi: 10.1016/j.clinthera.2009.11.011. Review.

PMID:
20110041
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk